Combination therapy shows promising progression-free survival in advanced non-small cell lung cancer patients with high PD-L1 expression
Early trial shows two-drug combo may help advanced lung cancer patients
This randomized phase 2 trial evaluated domvanalimab plus zimberelimab compared to zimberelimab alone or chemotherapy in patients with advan…
A Phase 2 trial suggests a two-drug combination might improve outcomes for some patients with advanced lung cancer compared to standard chem…
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors.
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Global disparities persist in access to molecular diagnostics and novel therapies for advanced NSCLC
Why does where you live still determine your lung cancer care?
A narrative review synthesizing evidence from guidelines and real-world studies describes persistent global disparities in access to molecul…
Where you live still decides if you get advanced lung cancer tests and treatments, creating a harsh reality where geography and income deter…